JPMorgan raised the firm’s price target on Novartis (NVS) to CHF 135 from CHF 125 and keeps an Overweight rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis price target raised to EUR 135 from EUR 125 at Deutsche Bank
- ESIH, XSDR, HLTH: These ETFs Provide Exposure to Europe’s Top Healthcare Companies
- Sustained Growth Beyond Patent Cliffs: Confidence in Novartis’ Pipeline-Driven Upside to 2030
- Novartis’ treatment of progressive supranuclear palsy granted orphan designation
- Novartis downgraded to Hold from Buy at DZ Bank